Source: FDA, National Drug Code (US) Revision Year: 2023
EXXUA contains gepirone, in the salt form as gepirone hydrochloride (HCl). The chemical name is 2,6- piperidinedione,4,4-dimethyl-1-[4-[4-(2-pyrimidinyl)-1-piperazinyl]butyl]-, monohydrochloride. The molecular weight of gepirone HCl is 395.93 and the structural formula is as follows:
Gepirone HCl is a white to off-white crystalline powder, which is readily soluble in water.
EXXUA is supplied as extended-release tablets for oral administration. Each extended-release tablet contains 18.2 mg, 36.3 mg, 54.5 mg, or 72.6 mg, gepirone equivalent to 20 mg, 40 mg, 60 mg, or 80 mg of gepirone HCl respectively. The extended-release tablets also contain the following inactive ingredients: colloidal silicon dioxide, Hypromellose, iron oxide (red and/or yellow colorants), magnesium stearate, and microcrystalline cellulose.
Dosage Forms and Strengths |
---|
EXXUA is available as extended-release tablets in the following strengths, as gepirone base:
|
How Supplied |
---|
EXXUA (gepirone) extended-release tablets are supplied in bottles of 100 with child-resistant caps and in four dosage strengths:
Manufactured by: Distributed by: MISSION PHARMACAL COMPANY Fabre-Kramer Pharmaceuticals, Inc., San Antonio, TX 78230 1355 Houston, TX 77057 |
Drug | Countries | |
---|---|---|
EXXUA | United States |
© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.